哪些PSMA-PET阴性前列腺癌患者可安全避免活检:迈向基于PSMA的无活检策略新一步
本研究基于前瞻性活检队列(NCT05073653)中111例治疗初治且PSMA-PET阴性(PRIMARY评分1/2)的男性,评估其避免或延迟前列腺活检的可能性。年轻年龄是非临床显著前列腺癌(csPCa)的独立预测因子(P=0.006)。PSMA-PET对csPCa的阴性预测值随年龄降低而提升:全部人群88%,<65岁98%(98% vs 88%,P=0.021),<60岁100%(100% vs 88%,P=0.040)。作者初步提出,<65岁且PSMA-PET阴性(PRIMARY 1或2)者可考虑省略或推迟活检。
要点
- 111例PSMA-PET阴性(PRIMARY评分1/2)治疗初治男性中,csPCa患病率为57%,任何级别前列腺癌患病率为65%。
- PSMA-PET对csPCa的阴性预测值:全部88%,<65岁98%,<60岁100%。
- 作者初步提出,<65岁且PSMA-PET阴性(PRIMARY 1或2)者可考虑省略或推迟前列腺活检。
核心结论
- 作者初步提出,对于年龄<65岁且PSMA-PET阴性(PRIMARY评分1或2)的男性,应考虑省略或推迟前列腺活检。
- 相反,对于年龄≥65岁、活检初治且临床高度怀疑前列腺癌的男性,尽管PSMA-PET阴性,仍可考虑进行前列腺活检。
- 需要进一步的前瞻性及外部评估来验证这一新策略的稳健性。
研究设计与样本
- 本研究为前瞻性活检队列(NCT05073653)中的分析,连续纳入341例,其中111例治疗初治且PSMA-PET阴性(PRIMARY评分1/2)的男性被纳入分析。
- 所有参与者均接受PSMA-PET和组织病理学检查。
- 临床显著前列腺癌(csPCa)定义为Grade Group≥2。
- 采用多变量逻辑回归识别非csPCa的预测因子,采用受试者工作特征(ROC)分析检测前列腺病理上的非csPCa。
- 另外回顾性审查了PSMA阳性患者的影像学和病理学结局。
主要发现
- 较年轻年龄被确定为csPCa缺失的独立预测因子(P=0.006)。
- ROC分析显示,在整个PSMA阴性队列和MRI亚组中,单独年龄的曲线下面积最大分别为0.77(0.67-0.87)和0.78(0.68-0.88)(均P<0.001)。
- PSMA-PET对csPCa检测的阴性预测值随年龄降低而改善:全部人群为88%,<65岁男性为98%(98% vs 88%,P=0.021),<60岁男性为100%(100% vs 88%,P=0.040)。
- 当联合阴性MRI时,PSMA-PET的阴性预测值从88%提升至94%;在阴性MRI且年龄<65岁的男性中提升至100%。
- csPCa的患病率为57%,任何级别前列腺癌的患病率为65%。
关键数值与推荐
- csPCa定义为Grade Group≥2。
- PSMA-PET阴性定义为PRIMARY评分1/2。
- PSMA-PET对csPCa的阴性预测值:全部人群88%,<65岁98%(98% vs 88%,P=0.021),<60岁100%(100% vs 88%,P=0.040)。
- 联合阴性MRI后PSMA-PET的阴性预测值:总体94%,阴性MRI且<65岁男性100%。
- csPCa患病率57%,任何级别前列腺癌患病率65%。
临床怎么用
- 作者初步提出,对于年龄<65岁且PSMA-PET阴性(PRIMARY评分1或2)的男性,应考虑省略或推迟前列腺活检。
- 作者提出,对于年龄≥65岁、活检初治且临床高度怀疑前列腺癌的男性,尽管PSMA-PET阴性,仍可考虑进行前列腺活检。
- 作者指出,需要进一步的前瞻性及外部评估来验证该新策略的稳健性。
局限性
- 需要进一步的前瞻性及外部评估来证明这一新策略的稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to identify if a subset of men can safely avoid or delay prostate biopsy based on negative results of prostate-specific membrane antigen positron emission tomography (PSMA-PET). MATERIALS AND METHODS: Among 341 consecutive cases in a prospective biopsy cohort (NCT05073653), 111 treatment-naïve men with negative PSMA-PET (PRIMARY-score 1/2) were included. All participants underwent PSMA-PET and histopathological examinations. Clinically significant prostate cancer (csPCa) was defined as Grade Group ≥ 2. Multivariate logistic regression was employed to identify predictors of non-csPCa. Receiver operating characteristic (ROC) analysis was performed to detect non-csPCa on prostate pathology. PSMA-postive patients were additionally reviewed to assess the imaging and pathological outcomes. RESULTS: Younger age was identified as an independent predictor (P = 0.006) for the absence of csPCa. ROC analysis of csPCa revealed the largest areas under the curve of 0.77 (0.67-0.87) and 0.78 (0.68-0.88) for individual age in the entire PSMA-negative cohort and the MRI subset, respectively (both P < 0.001). The negative predictive value (NPV) of PSMA-PET for csPCa detection improved with a decreasing age, from 88% in all, to 98% in men aged under 65 yrs (98% vs. 88%, P = 0.021), and to 100% in men aged under 60 yrs (100% vs. 88%, P = 0.040). The NPV of PSMA-PET improved from 88 to 94% when combined with negative MRI, and to 100% in men with negative MRI and aged under 65 yrs. The prevalence was 57% for csPCa and 65% for PCa of any grade. CONCLUSION: We preliminarily propose that omission or postponement of prostate biopsy should be considered for men under the age of 65 yrs with negative PSMA-PET scored as PRIMARY 1 or 2. Conversely, prostate biopsy might be considered in biopsy-naïve men aged 65 yrs or older with strong clinical suspicion of PCa, despite negative PSMA-PET. Further prospective and external evaluation is needed to prove the robustness of this novel strategy.
引用
- Li Y, Yang J, Xiao L, et al. Which patients with negative PSMA-PET imaging can safely avoid biopsy for prostate cancer? a novel step towards PSMA-based biopsy-free strategy. Eur J Nucl Med Mol Imaging. 2025. PMID: 39862259. doi:10.1007/s00259-025-07089-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。